Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

The Lancet

Volumn 374, Issue 9683, 2009, Pages 26-

  Segura, J ^a   Ruilope, LM ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG RESPONSE; GLOMERULUS FILTRATION RATE; HUMAN; LETTER; PRIORITY JOURNAL; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; METABOLISM; METHODOLOGY; NOTE; RISK REDUCTION; TREATMENT OUTCOME;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FLUOROBENZENES; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; PYRIMIDINES; RESEARCH DESIGN; RISK REDUCTION BEHAVIOR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 67649424334     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61233-2     Document Type: Letter

References (4)

1. Ridker P.M., Danielson E., Fonseca F., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373 (2009) 1175-1182
2. Ridker P.M., Danielson E., Fonseca F., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
3. Tonelli M., Isles C., Curhan G.C., et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110 (2004) 1557-1563
4. Navaneethan S.D., Pansini F., Perkovic V., et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2 (2009) CD007784.